Two key geographic clusters dominate the biotech landscape today. These two areas, Boston and San Francisco, combine a unique blend of biomedical science, venture capital, entrepreneurial talent, risk-taking culture, and geographic density. Other regions have some or all of these elements, but not in the same magnitude or momentum that Boston and San Francisco have today – and the gap is just getting bigger.
A national security threat equivalent to terrorism? This is how Britain’s chief medical officer described drug-resistant bacteria. Dr. Thomas Frieden, recently retired director of the CDC, referred to drug resistant bacteria as one of the most serious health threats that “has the potential to harm or kill anyone in the country, undermine modern medicine, to devastate our economy and to make our health care system less stable.”
This guest blog was written by Troy Lister, Head of Chemistry, and Cristina Larkin, Chief Commercial Officer, of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC.
As a biotech investor, it’s been fascinating to watch the Snapchat IPO and the fanfare around this $25B sensation following its offering as a “camera” company. As one of the big tech unicorns, it’s justifiably gotten considerable attention in the media and tech community. Despite the pullback in value since the offering, it remains a monster win. Kudos to Lightspeed and Benchmark, who have generated returns in the billions.
Despite the volatility of biotech stocks in the public markets, the VC-backed private biotech ecosystem has been in remarkable equilibrium for much of the last decade.
Despite the growing problem of drug-resistant bacteria, few new antibiotics have been developed in recent decades. Spero Therapeutics is trying to fill that gap by assembling a pipeline of antibiotic candidates, and it now has $51.7 million in new capital to finance clinical trials on some of them.